EuroBiotech: More Articles of Note

TiGenix priced its Nasdaq IPO, both the U.K.'s ABPI and Europe's EFPIA gained new leaders, while Ipsen lost its CSO.

> Ipsen has said that Claude Bertrand will step down as EVP, R&D and CSO with Alexandre Lebeaut to lead its research and development division in the interim. Capital story

> AstraZeneca’s U.K. head Lisa Anson has been elected as the next president of the Association of the British Pharmaceutical Industry (ABPI), the main pharma R&D trade group in Britain, starting in April. Release

> The European trade group for pharma R&D is also going through changes at the top, as EFPIA announces its long-term director-general Richard Bergström is to leave. EFPIA said it has appointed Eric Cornut as its interim director general. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Belgium biotech TiGenix has raised $35.65 million gross under its Nasdaq IPO, representing 46 million ordinary shares, at a price to the public of $15.50—a 14% discount on its shares. The company, which works on injectable stem cell therapies for perianal fistulas, plans to list on the Nasdaq under the symbol $TIG. Release

Suggested Articles

Quest Diagnostics has launched three new test kits for STDs that consumers can order online, within the privacy of their own home.

Digital imaging analysis provider Aidoc has raised $27 million to help build out its go-to-market team, after processing its one-millionth CT scan.

Two months of treatment with the diabetes drug Jardiance reduced pulmonary congestion and biomarkers of heart failure in pig models.